Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon in HDV infection

F Rosina1, R Cozzolongo

  • 1Experimental Department of Gastroenterology, Molinette Hospital, Torino, Italy.

Antiviral Research
|July 1, 1994
PubMed
Summary

Current treatments for chronic hepatitis D are unsatisfactory. New therapies targeting hepatitis B virus (HBV) are needed for this severe liver disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Worldwide prevalence, genotype distribution and management of hepatitis C.

Acta gastro-enterologica Belgica·2021
Same author

Ulcerative proctitis in out-patient practice: an unexpected clinical challenge.

Minerva gastroenterologica e dietologica·2014
Same author

Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2013
Same author

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Diabetologia·2012
Same author

Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2011
Same author

The obesity gene and colorectal cancer risk: a population study in Northern Italy.

European journal of internal medicine·2011

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis D is a severe liver disease caused by the hepatitis delta virus (HDV), which requires hepatitis B virus (HBV) for replication.
  • Alpha interferon (IFN) is the current standard treatment but yields unsatisfactory results for chronic hepatitis D.
  • Antiviral agents like Ribavirin have shown limited efficacy in clinical settings.

Purpose of the Study:

  • To review the current treatment landscape for chronic hepatitis D.
  • To identify limitations of existing therapies, particularly interferon (IFN).
  • To explore potential new therapeutic targets and strategies for chronic hepatitis D.

Main Methods:

  • Review of existing literature on chronic hepatitis D treatment.
  • Analysis of the efficacy of interferon (IFN) based on infection duration, dosage, and treatment length.
  • Evaluation of in vitro and in vivo studies on antiviral agents targeting HDV and HBV.

Main Results:

  • Interferon (IFN) is most effective in recent infections (<1 year) with high doses (9-10 MU thrice weekly) for at least 12 months.
  • Predicting sustained response to IFN is challenging, with HBsAg clearance and anti-HBs seroconversion occurring long after treatment.
  • Antiviral agents like Ribavirin have failed to demonstrate clinical efficacy against HDV.
  • HBV is identified as a potential target for antiviral therapy in chronic hepatitis D.

Conclusions:

  • Existing treatments for chronic hepatitis D, including IFN, are largely unsatisfactory.
  • There is a critical need for novel therapeutic options for chronic hepatitis D.
  • Targeting HBV with new deoxynucleotide analogues presents a promising strategy for managing chronic hepatitis D.

Related Experiment Videos